trientine has been researched along with Diabetes Mellitus, Type 2 in 3 studies
Trientine: An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.
TETA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 8 and 11 of a fouteen-membered ring are each substituted with a carboxymethyl group.
2,2,2-tetramine : A polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trientine treatment decreased LVM(bsa) by 5." | 2.74 | A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study. ( Baker, JR; Brunton, DH; Cooper, GJ; Cowan, BR; Dissanayake, AM; Doughty, RN; Frampton, CM; Gamble, GD; Occleshaw, CJ; Phillips, AR; Poppitt, SD; Young, AA, 2009) |
| " Twenty-four-hour urine collections were performed before and after dosing participants." | 1.34 | Triethylenetetramine and metabolites: levels in relation to copper and zinc excretion in urine of healthy volunteers and type 2 diabetic patients. ( Chan, YK; Cooper, GJ; Gamble, GD; Lu, J; Othman, AA; Poppitt, SD, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cooper, GJ | 2 |
| Young, AA | 1 |
| Gamble, GD | 2 |
| Occleshaw, CJ | 1 |
| Dissanayake, AM | 1 |
| Cowan, BR | 1 |
| Brunton, DH | 1 |
| Baker, JR | 1 |
| Phillips, AR | 1 |
| Frampton, CM | 1 |
| Poppitt, SD | 2 |
| Doughty, RN | 1 |
| Baynes, JW | 1 |
| Murray, DB | 1 |
| Lu, J | 1 |
| Chan, YK | 1 |
| Othman, AA | 1 |
1 trial available for trientine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study.
Topics: Adult; Aged; Blood Pressure; Body Surface Area; Chelating Agents; Creatinine; Diabetes Mellitus, Typ | 2009 |
2 other studies available for trientine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
The metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the Zucker diabetic rat.
Topics: Animals; Chelating Agents; Citric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Evalu | 2009 |
Triethylenetetramine and metabolites: levels in relation to copper and zinc excretion in urine of healthy volunteers and type 2 diabetic patients.
Topics: Adult; Aged; Chelating Agents; Copper; Diabetes Mellitus, Type 2; Humans; Male; Middle Aged; Trienti | 2007 |